23 October 2020
Oakley Capital Investments Limited
Oakley Capital Investments Limited1(the "Company"), was notified on 22 October 2020 of the following transaction by a Director of the Company:
Fiona Beck, a Director of the Company, has purchased 11,600 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 256.00 pence per Ordinary Share. As a result, Fiona Beck is now interested in 11,600 Ordinary Shares of the Company, representing 0.006% per cent. of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely associated
Reason for the notification
Initial notification/ Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Oakley Capital Investments Limited
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary Shares of 1p each
Nature of the transaction
Price(s) and volume(s)
- Aggregated volume
N/A (single transaction)
Date of the transaction
22 October 2020
Place of the transaction
London Stock Exchange, Specialist Fund Segment
- ends -
For further information please contact:
Oakley Capital Limited
+44 20 7766 6900
Steven Tredget, Investor Relations
Greenbrook Communications Limited
+44 20 7952 2000
Alex Jones / Gina Bell / James Williams
Liberum Capital Limited (Financial Adviser & Broker)
+44 20 3100 2000
Gillian Martin / Owen Matthews
This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014
LEI Number: 213800KW6MZUK12CQ815
1 About Oakley Capital Investments Limited ("OCI")
OCI is a Specialist Fund Segment ("SFS") traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds2.
A video introduction to OCI is available at https://oakleycapitalinvestments.com/videos/
Oakley Capital, the Investment Adviser
Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.
The Oakley Funds
Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV and Oakley Capital Origin Fund are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.
Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.
The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.
Kallelse till extra bolagsstämma i NanoCap Group AB
Aktieägare som vill delta i stämman ska dels vara upptagen i utskrift av aktieboken avseende förhållandena den 24 oktober 2023, dels anmäla sig till bolaget senast den 27 oktober 2023 skriftligen till Box 5141, 102 43 Stockholm eller via e-post till [email protected]. Anm...
Bioextrax: Capacity to accommodate rising interest
American start-up company exercises option for the next periodWarrants subscription adds SEK 10.6 million before issue costsOur model implies a fair valuation of SEK 10.5 per shareBioextrax shows continued progress in its Q2 report for 2023. The company signed a license agreement with the US start-u...